In conclusion, our investigation of the intercellular transfer of KRAS via TNTs has elucidated a novel mechanism by which a tumor-driving mutant protein can be trafficked and distributed among cancer cells, in this case colon cancer cells specifically. This evidence concerns the gene KRAS and malignant colon neoplasm.